Quest Diagnostics Incorporated - Asset Resilience Ratio

Latest as of December 2025: 2.59%

Quest Diagnostics Incorporated (DGX) has an Asset Resilience Ratio of 2.59% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Quest Diagnostics Incorporated carry for a breakdown of total debt and financial obligations.

Liquid Assets

$420.00 Million
Cash + Short-term Investments

Total Assets

$16.23 Billion
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2009–2025)

This chart shows how Quest Diagnostics Incorporated's Asset Resilience Ratio has changed over time. See Quest Diagnostics Incorporated shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Quest Diagnostics Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Quest Diagnostics Incorporated market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $420.00 Million 2.59%
Short-term Investments $0.00 0%
Total Liquid Assets $420.00 Million 2.59%

Asset Resilience Insights

  • Limited Liquidity: Quest Diagnostics Incorporated maintains only 2.59% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Quest Diagnostics Incorporated Industry Peers by Asset Resilience Ratio

Compare Quest Diagnostics Incorporated's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Agilent Technologies Inc
NYSE:A
Diagnostics & Research 12.22%
Leveljump Healthcare Corp
V:JUMP
Diagnostics & Research 32.45%
StageZero Life Sciences Ltd
TO:SZLS
Diagnostics & Research 81.79%
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%

Annual Asset Resilience Ratio for Quest Diagnostics Incorporated (2009–2025)

The table below shows the annual Asset Resilience Ratio data for Quest Diagnostics Incorporated.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 2.59% $420.00 Million $16.23 Billion -0.81pp
2024-12-31 3.40% $549.00 Million $16.15 Billion -1.49pp
2023-12-31 4.89% $686.00 Million $14.02 Billion +2.44pp
2022-12-31 2.45% $315.00 Million $12.84 Billion -4.28pp
2021-12-31 6.73% $916.00 Million $13.61 Billion -5.24pp
2020-12-31 11.97% $1.68 Billion $14.03 Billion +2.69pp
2019-12-31 9.28% $1.19 Billion $12.84 Billion +8.05pp
2018-12-31 1.23% $135.00 Million $11.00 Billion -0.08pp
2017-12-31 1.30% $137.00 Million $10.50 Billion -2.25pp
2016-12-31 3.55% $359.00 Million $10.10 Billion --
2015-12-31 0.00% $0.00 $9.96 Billion --
2014-12-31 0.00% $0.00 $9.88 Billion --
2013-12-31 0.00% $0.00 $8.95 Billion --
2012-12-31 0.00% $0.00 $9.28 Billion --
2011-12-31 0.00% $0.00 $9.31 Billion --
2010-12-31 0.00% $0.00 $8.53 Billion --
2009-12-31 0.00% $0.00 $8.56 Billion --
pp = percentage points

About Quest Diagnostics Incorporated

NYSE:DGX USA Diagnostics & Research
Market Cap
$20.85 Billion
Market Cap Rank
#1242 Global
#495 in USA
Share Price
$189.13
Change (1 day)
-0.90%
52-Week Range
$166.42 - $211.91
All Time High
$211.91
About

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics … Read more